关于嘉晨西海
嘉晨西海(杭州/上海)生物技术有限公司是一家专注于自复制和常规RNA新药和疫苗开发的创新药研发新锐。2019年成立以来，公司发展稳健迅速，目前已经建立了一整套适合商业化生产的mRNA合成、纯化、分析质控工艺，并研发了表达效力更高的通用mRNA模板(包括自复制和非自复制RNA)。借助于其高效的筛选平台，嘉晨西海开发了包括聚合物和纳米脂质体颗粒在内的一整套mRNA递送系统。嘉晨西海拥有多个自主知识产权的分别适用于肌肉、静脉、组织靶向给药的阳离子脂复合体。公司的管线涵盖肿瘤免疫治疗、传染病疫苗、罕见病和医学美容。公司的肿瘤免疫和传染病疫苗项目正快速进入临床试验阶段。
About Immorna
Immorna is afast-growing biotech company that focuses on developing self-replicating andconventional RNA-based therapeutics and vaccines. Since its founding, Immornahas built a robust CMC platform for mRNA synthesis, purification, andanalytical testing that is well suited for clinical and commercial development.In addition, with its state-of-the-art screening tools Immorna has developed anarsenal of mRNA delivery vehicles including polymers and lipid nanoparticlesfeaturing multiple proprietary ionizable cationic lipids suitable forintramuscular, intravenous or tissue-targeting delivery. Immorna has a diversepipeline spanning cancer immunotherapy, infectious diseases, rare geneticdiseases, and cosmetology.
Immorna's footprintincludes Hangzhou and Shanghai in China, and RTP, NC in the US.
